AlphAIAlphAI — Financial news for AI agents
azat.tvSEP 132 min read$AMGN

Amgen Stock Faces Pressure After Rival’s Clinical Trial Miss

Amgen Inc. (AMGN) stock fell 5% to $415 after Novartis's Lp(a)-lowering therapy failed a clinical trial, raising concerns about Amgen's similar drug, olpasiran. Analysts note Amgen's diversification may limit further declines.

Original reporting
azat.tv
Published Sep 13, 2026, 10:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 11:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Amgen Stock Faces Pressure After Rival’s Clinical Trial Miss — source image
Source · azat.tv
Decision brief

The 30-second read

$AMGNBearishHigh
01

Why it matters

Amgen’s share price drop reflects investor concern over its own Lp(a) asset, olpasiran, despite earlier promising data.

02

Market read

The news creates immediate downside pressure on Amgen and may influence valuation of other Lp(a) developers.

03

What to watch

Amgen’s diversified pipeline (obesity, cholesterol, asthma) could cushion longer‑term performance.

Relevance 8/10Novelty 8/10Timing: after‑hours reaction

Background

Novartis’s pelacarsen Phase 3 miss raised doubts about the clinical benefit of deep Lp(a) lowering, affecting peers.

Company-level read

Ticker impact

$AMGNBearishHigh confidence
Context

Amgen stock fell ~5% to $415 after Novartis trial failure raised concerns on its Lp(a) program.

Expected impact

Potential further decline if additional data on olpasiran remain uncertain; short‑term support may hold around $410‑$415.

Evidence & confidence

5% intraday move and $12 B market‑cap loss indicate material impact; no new data from Amgen itself, but market reacts to peer trial.

Market effects

Sector

Biotech/Lp(a) therapeutic space may see broader risk reassessment.

Regional

U.S. biotech stocks could face short‑term pressure.

Global

Limited to companies with similar Lp(a) programs worldwide.

Counterpoint

What could challenge this read

Amgen’s olpasiran still shows stronger Phase 2 Lp(a) reduction; the market may overreact.

Key entities

  • company
    Amgen Inc.

    U.S. biotech firm with Lp(a) program olpasiran.

  • company
    Novartis AG

    Competitor whose failed trial triggered market reaction.

Read at source← All news

Related articles

SEP 14
$NVSMedAI 9/10

Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock.

Novartis' pelacarsen failed to meet its primary endpoint in a late-stage study, impacting the cardiovascular drug market. Analysts expected peak sales of $4B-$5B. Eli Lilly's (LLY) stock declined only 3%, as its lepodisiran drug uses a different approach and Lilly has strong diabetes/obesity markets. Novartis (NVS) and Amgen (AMGN) are also developing Lp(a)-lowering drugs.

fool.com3 min
SEP 13
$NVSMedAI 8/10

Novartis’ Failed Cholesterol Drug Trial Sends Ionis and Amgen Tumbling

Novartis' experimental drug Pelacarsen, developed with Ionis, failed to reduce cardiovascular events in a major trial. Novartis (NYSE:NVS) and Ionis (NASDAQ:IONS) shares dropped, as did Amgen (NASDAQ:AMGN) due to read-through concerns. Analysts had predicted peak sales of $3-6B for Pelacarsen. Amgen's similar drug, olpasiran, is still in trials. The failure raises questions about the effectiveness of Lp(a)-lowering drugs.

insidermonkey.com2 min
SEP 13
$AMGNMedAI 8/10

Is Amgen (AMGN) Fully Valued As New IMDELLTRA Data Reshapes The Story?

Amgen (AMGN) reported Phase 3 data for IMDELLTRA combined with AstraZeneca’s Imfinzi, showing improved survival rates in small cell lung cancer. The stock has seen mixed returns recently, with a 13.70% drop over 7 days but a 40.32% gain over 1 year. Analysts debate its valuation, with fair value estimates ranging from $359.98 to $669.81, highlighting risks and growth potential.

simplywall.st3 min
SEP 11
$AMGNHighAI 8/10

Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Amgen (AMGN) and Revolution Medicines (RVMD) present contrasting investment profiles. Amgen, with $36.7B revenue and $7.7B net income in 2025, offers steady cash flows and a 2.60% dividend. Revolution Medicines, a clinical-stage biotech, has no revenue but reported a $1.1B net loss. Revolution recently gained FDA approval for Daraxonrasib, a potential breakthrough in pancreatic cancer treatment.

fool.com3 min
SEP 11
$AMGNHighAI 9/10

Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca

Amgen (AMGN) and AstraZeneca (AZN) reported positive late-stage trial results for their combination therapy, Imdelltra and Imfinzi, in extensive-stage small-cell lung cancer. The treatment improved overall survival, progression-free survival, and response rates. Imdelltra generated $513M in sales last year, and the results could expand its use. Amgen's Q2 2026 revenue rose 10%, while AstraZeneca faces investor pressure from recent setbacks.

yahoo.com2 min